Actively Recruiting
Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
Led by Samsung Medical Center · Updated on 2024-11-06
560
Participants Needed
1
Research Sites
319 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
CONDITIONS
Official Title
Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 19 years of age
- Diagnosed with acute myocardial infarction (STEMI or NSTEMI) complicated by cardiogenic shock classified as SCAI Shock C, D, or E
- Currently requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO)
- Coronary lesions suitable for planned primary PCI as decided by the treating physician
- Presence of multi-vessel coronary artery disease
You will not qualify if you...
- Shock caused by conditions other than cardiogenic shock, such as hypovolemia, sepsis, or obstructive shock
- Shock due to mechanical complications from myocardial infarction (e.g., rupture of papillary muscle, ventricular septum, or free wall)
- Unwitnessed out-of-hospital cardiac arrest with a Glasgow coma scale less than 8 after return of spontaneous circulation
- Single-vessel coronary artery disease
- Onset of shock more than 24 hours prior to enrollment
- Known allergy or intolerance to heparin
- Severe other diseases with life expectancy less than 6 months
- Pregnancy or currently breastfeeding
- Having a do-not-resuscitate (DNR) order
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
J
Jeong Hoon Yang, MD
CONTACT
K
Ki Hong Choi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here